story of the week
Five-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
J. Clin. Oncol 2022 Feb 02;[EPub Ahead of Print], DR Spigel, C Faivre-Finn, JE Gray, D Vicente, D Planchard, L Paz-Ares, JF Vansteenkiste, MC Garassino, R Hui, X Quantin, A Rimner, YL Wu, M Özgüroğlu, KH Lee, T Kato, M de Wit, T Kurata, M Reck, BC Cho, S Senan, J Naidoo, H Mann, M Newton, P Thiyagarajah, SJ AntoniaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.